The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Preliminary Clinical Validity
Christopher Randolph;Michael C. Tierney;Erich Mohr;Thomas N. Chase.
Journal of Clinical and Experimental Neuropsychology (1998)
Alzheimer's disease: Focal cortical changes shown by positron emission tomography
Norman L. Foster;Thomas N. Chase;Paul Fedio;Nicholas J. Patronas.
Limbic System Abnormalities Identified in Schizophrenia Using Positron Emission Tomography With Fluorodeoxyglucose and Neocortical Alterations With Deficit Syndrome
Carol A. Tamminga;Gunvant K. Thaker;Robert Buchanan;Brian Kirkpatrick.
Archives of General Psychiatry (1992)
D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects
Judith R. Walters;Debra A. Bergstrom;Joanne H. Carlson;Thomas N. Chase.
Degradation of α-Synuclein by Proteasome *
M. Catherine Bennett;John F. Bishop;Yan Leng;P. Boon Chock.
Journal of Biological Chemistry (1999)
Cortical abnormalities in Alzheimer's disease
N. L. Foster;T. N. Chase;L. Mansi;R. Brooks.
Annals of Neurology (1984)
L-Dopa-Induced Release of Cerebral Monoamines
K. Y. Ng;T. N. Chase;R. W. Colburn;I. J. Kopin.
Dopaminergic modulation of cortical function in patients with Parkinson's disease.
Venkata S. Mattay;Alessandro Tessitore;Joseph H. Callicott;Alessandro Bertolino.
Annals of Neurology (2002)
A comparison of the anatomical distribution of substance P and substance P receptors in the rat central nervous system
Clifford W. Shults;Remi Quirion;Bibie Chronwall;Thomas N. Chase.
Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys
Stella M. Papa;Thomas N. Chase.
Annals of Neurology (1996)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: